XCL1 and neoplasm: These agents, in combination with OVs, also act on several other aspects of the tumor adaptive immunity and TME, but mainly act through reducing the function of immunosuppressive cells, such as MDSCs, which in turn change cytokine levels (IL-1b, IL-6 and C-X-C motif chemokine ligand 1 (CXCL1)) and amplify the CD4+ and CD8+-mediated tumor regression [109,110,117,246].